Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Rifabutin has good chemical stability and low drug resistance rate in acidic gastric
environment. Therefore, it is often used in combination with amoxicillin proton pump
inhibitor for the rescue treatment of Helicobacter pylori. The purpose of this study was to
evaluate the efficacy and safety of rifabutin-containing triple therapy versus classical
bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory
Helicobacter pylori